


Toceranib Phosphate

Chemical Properties

CAS No. :	874819-74-6
Formula:	C22H28FN4O6P
Molecular Weight:	494.45
Storage:	Store at low temperature Powder: -20°C for 3 years In solvent: -80°C for 1 year <small>Actual storage temperature shall be subject to the COA.</small>



Biological Description

Description	Toceranib Phosphate (SU11654 phosphate), is a selective inhibitor of the tyrosine kinase activity of several members of the split kinase RTK family, including Flk-1/KDR, PDGFR
Targets(IC50)	c-Kit,PDGFR,Tyrosinase,VEGFR
In vivo	Systolic blood pressure was significantly ($P = 0.0013$) higher in previously normotensive treatment dogs after initiation of treatment with toceranib phosphate ($152 \text{ mmHg} \pm 19$) compared to baseline ($136 \text{ mmHg} \pm 14$). 37% of treated dogs developed $\text{SBP} \geq 160 \text{ mmHg}$. The prevalence of systemic hypertension (37%) and proteinuria (21%) at baseline in treatment dogs did not differ from that of age-matched healthy controls (15% [$P = 0.13$] and 0% [$P = 0.069$], respectively)[1].
Animal Research	Dogs scheduled to received toceranib phosphate treatment were divided into 2 groups based on SBP recorded at screening: dogs that were normotensive were assigned to Group 2a and dogs diagnosed with HT were assigned to Group 2b. After baseline evaluation, dogs enrolled in Group 2a received toceranib phosphate at a standard dose as previously published.2 Group 2b dogs received toceranib phosphate as described, but were also treated with standard-of-care treatment for HT, including amlodipine besylate (0.2-0.4 mg/kg PO q 24 hours), enalapril maleate (0.5 mg/kg PO q 12 hours), or both, initiated at the discretion of the attending veterinarian. Some dogs were treated with additional medications, including corticosteroids, at the discretion of the oncologist. All dogs were re-evaluated on Day 14 (± 3 days) at which time a UPC and blood pressure measurements were performed[1].

Solubility Information

Solubility	DMSO: Slightly soluble, ($< 1 \text{ mg/ml}$ refers to the product slightly soluble or insoluble)
------------	---

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.0224 mL	10.1122 mL	20.2245 mL
5 mM	0.4045 mL	2.0224 mL	4.0449 mL
10 mM	0.2022 mL	1.0112 mL	2.0224 mL
50 mM	0.0404 mL	0.2022 mL	0.4045 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Tjostheim S S , Stepien R L , Markovic L E , et al. Effects of Toceranib Phosphate on Systolic Blood Pressure and Proteinuria in Dogs[J]. Journal of Veterinary Internal Medicine, 2016, 30(4):951-957.

London C , Mathie T , Stingle N , et al. Preliminary evidence for biologic activity of toceranib phosphate (Palladia?) in solid tumours[J]. Veterinary & Comparative Oncology, 2012, 10(3):0-0.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only· Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481